Shanghai, China, 23 February 2021 – Shanghai MicroPort MedBot (Group) Co., Ltd. (MicroPort® MedBot) recently announced the completion of patient enrollment for clinical trials of the Toumai® Endoscopic Surgery Robotic System (Toumai®). This milestone means Toumai® is China’s first domestically manufactured endoscopic robot for multicenter clinical trials in the field of urology.
According to Dr. Chao He, President of MicroPort® MedBot, “Through joint efforts of experts and teams from various clinical centers, we have successfully completed the enrollment for clinical trials of Toumai®, which is a demonstration of our determination to strive for excellence in independent endoscopic robot development.”
As an endoscopic surgery robotic system independently developed by MicroPort® MedBot, Toumai® consists of three parts: patient cart, video trolley, and surgeon console, which demonstrates obvious advantages in assisting with endoscopic surgeries, especially complex ones for which open surgery or conventional laparoscopic approach is too challenging. The high dexterity of the robotic wrist, realistic 3D views provided by the endoscopic system, as well as the intuitive and easy-to-use master-slave remote control offer great benefits in clinical use because they help to simplify surgical operations and shorten operation time.
Participants of the Toumai® clinical trials include the First Affiliated Hospital of PLA Naval Military Medical University (Shanghai Changhai Hospital), Zhongshan Hospital Affiliated to Fudan University, Renji Hospital affiliated to the School of Medicine, Shanghai Jiaotong University, and Zhejiang Provincial People's Hospital.
During the enrollment period, Toumai® had already assisted clinical experts to make breakthroughs and reach milestones of significant clinical value by completing a number of difficult urological surgeries, including the first domestic robot-assisted radical prostatectomy, partial nephrectomy, and retroperitoneal approach to partial nephrectomy. The success has proved the technical strength of MicroPort®’s independently developed endoscopic surgical robots to assist with complex surgeries in narrow anatomical space
Compared with similar imported products, Toumai® provides improved vision and operational support. Its successful application in a series of challenging and complex urological surgeries have won applause from experts at multiple clinical centers. Toumai® entered into the special approval procedure (“Green Path”) for innovative medical devices of the National Medical Products Administration (NMPA) on October 17th, 2019, and steady progress is being made on its certification for mass production and marketing.
About MicroPort® MedBot
MicroPort® MedBot is a subsidiary of Shanghai MicroPort Medical (Group) Co., Ltd. (MicroPort®). MicroPort® started its strategic development of medical robots in 2014 and has since been engaged in independent research and development of endoscopic surgical robots. Over the years, MicroPort® MedBot has focused on the development and commercialization of minimally invasive and noninvasive surgical robots, with integrated solutions gradually created for multiple clinical applications on five “golden paths”, namely laparoscopy, orthopedics, vascular intervention, natural orifice surgery, and percutaneous puncture.